Slide 1: Genevant & Arbutus LNP Litigation
1 Genevant & Arbutus LNP Litigation Lindsay Androski Special Counsel, Genevant CEO, Arbutus Matt Gline CEO, Roivant
Slide 2: Forward-Looking Statements
For investor audiences only Forward - Looking Statements This presentation includes forward - looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than
Slide 3: Key Takeaways: LNP Litigation
For investor audiences only 3 We believe that both the Moderna COVID - 19 vaccine (SPIKEVAX) and Pfizer/BioNTech’s COVID - 19 vaccine (COMIRNATY) infringe multiple Genevant/Arbutus LNP patents In the ex - US Moderna litigation, initial court hearings and rulings are expected in 2026 Markman rulings
Slide 4: Genevant and Arbutus Corporate History
For investor audiences only Genevant and Arbutus Corporate History 2006 Protiva acquired Tekmira, another company working on LNP technology Roivant set out to assemble a leading global HBV company by merging OnCore Biopharma with Protiva/Tekmira to form Arbutus Biopharma Roivant and Arbutus launched
Slide 5: A Leading Nucleic Acid Delivery Company
For investor audiences only 5 A Leading Nucleic Acid Delivery Company • Industry - leading LNP delivery capabilities and IP portfolio • Selective collaboration business model, partnering with payload companies to develop innovative nucleic acid medicines • The first LNP technology to be part of an
Slide 6: Genevant/Arbutus IP Portfolio and Pending Litigation
For investor audiences only • Some of the US patents licensed by Genevant from Arbutus include: • Moderna previously sought to invalidate two of the particle composition patents referenced above with IPR challenges but was largely unsuccessful • Litigation is ongoing against Moderna in the US and ce
Slide 7: mRNA COVID-19 Vaccines Have Generated Over $145BN in Revenue
For investor audiences only 7 mRNA COVID - 19 Vaccines from Moderna and Pfizer/BioNTech Have Generated Over $145BN in Revenue Revenue as of 9/30/2025 Data and sales calculated from Evaluate and company docs from MRNA, PFE, and BNTX • Total SpikeVax Sales account for ~1/3 of mRNA vaccine sales to dat
Slide 8: Moderna Case
Moderna Case Z ae LLL A, LAAT, Z LL LT TT LEAP LT i : LLY aa Vi ; felvent ETP 1 \ : eee ee \
Slide 9: February 2022 Complaint Against Moderna Asserting Patent Infringement
For investor audiences only 9 In February 2022, Genevant and Arbutus Jointly Filed a Complaint Against Moderna Asserting Patent Infringement on Patents Related to LNP Technology Case filed in the US District Court for the District of Delaware asserting infringement of six patents Genevant and Arbutu
Slide 10: Moderna Patent Litigation Timeline: Years in the Making
For investor audiences only 10 Moderna Patent Litigation Timeline: Years in the Making Note: All references are to calendar years and are approximate and subject to change. The timing of the litigation - related event s noted above is subject to change, including at the discretion of the court. See
Slide 11: Summary Judgment Motions Filed in US Moderna Case
For investor audiences only 11 Summary Judgment Motions Filed in US Moderna Case Note: All references are to calendar years and are approximate and subject to change. The timing of the litigation - related event s noted above is subject to change, including at the discretion of the court. See Slide
Slide 12: Motions to Exclude Expert Testimony (Daubert)
For investor audiences only 12 Moderna’s Motions to Exclude Genevant/Arbutus’ Expert Testimony 1) Damages methodologies 2) Opinions regarding willful infringement 3) Fractionation testing 4) Opinions regarding infringement 5) Opinions regarding applicability of Section 1498 Genevant/Arbutus’ Motions
Slide 13: Key Upcoming Milestones in US Litigation
For investor audiences only Key Upcoming Milestones in US Litigation • Judge to rule on summary judgment motions, including decision on § 1498, before the jury trial in March • Judge will rule on Daubert motions, which could narrow the expert testimony allowed to be presented on both sides or impact
Slide 14: Overview of International Infringement Litigation
For investor audiences only 14 Overview of International Infringement Litigation; Accounts for Significant Portion of Ex - US SpikeVax Revenue All ex - US jurisdictions with cases pending bifurcate liability from damages and, with success in liability phase, typically issue injunction preventing fut
Slide 15: Pfizer Case
Pfizer Case aaa Tf Za LEE ee \ Lea TEETER EEE \ LEAL ‘ EPP PEE PETE ) \ q eee LPP E PP EEE LAPT P I LLL] LLL]
Slide 16: Pfizer/BioNTech Litigation Timeline to Date
For investor audiences only 16 Pfizer/BioNTech Litigation Timeline to Date Note: All references are to calendar years and are approximate and subject to change. The timing of the litigation - related event s noted above is subject to change, including at the discretion of the court. See Slide 2 for
Slide 17: Publicly Available Evidence Supports the Initial Filing of Our Case
For investor audiences only Publicly Available Evidence Supports the Initial Filing of Our Case Publicly Available Evidence Supporting the Case 1 • BioNTech had license to Genevant LNP Technology for use for specific cancer and rare liver disease targets dating back to 2018; contract described Genev
Slide 18: In Summary: LNP Litigation
For investor audiences only 18 In Summary: LNP Litigation We believe both Moderna’s and Pfizer/BioNTech’s COVID - 19 vaccines infringe multiple Genevant/Arbutus patents Trial/hearings in both the US and the ex - US litigation against Moderna expected in 2026 Awaiting court scheduling in the Pfizer/B
Slide 19: Key Takeaways: LNP Litigation
For investor audiences only 19 We believe that both the Moderna COVID - 19 vaccine (SPIKEVAX) and Pfizer/BioNTech ’s COVID - 19 vaccine (COMIRNATY) infringe multiple Genevant/Arbutus LNP patents In the ex - US Moderna litigation, initial court hearings and rulings are expected in 2026 Markman ruling